Stay updated on IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial page.

Latest updates to the IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedLocation details are consolidated under a single 'Locations' section, replacing the previous separate state-specific sections (Arizona, Florida, Iowa, Kansas, New York, Ohio, Tennessee, Texas, Utah). The page revision is updated to v3.3.3.SummaryDifference1%

- Check24 days agoNo Change Detected
- Check39 days agoChange DetectedThe page revision updated from v3.3.1 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check46 days agoChange DetectedThe page revision label updated from v3.2.0 to v3.3.1 with no visible changes to content or functionality.SummaryDifference0.1%

- Check53 days agoChange DetectedFunding status notice/banner was removed from the page, eliminating an administrative operating-status message; this does not affect the study details, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check67 days agoChange DetectedNo significant additions or deletions were observed on the page; the content appears unchanged.SummaryDifference0.4%

- Check96 days agoChange DetectedIntroducing a major status notice about government funding and NIH Clinical Center operations (including links to official sources) and updating the page version from v3.1.0 to v3.2.0.SummaryDifference3%

Stay in the know with updates to IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial page.